Patient gets PML on Zeposia...

So this is your selling expertise when MDs raise the concern... lololololol
Boy, we have a real winner in the ranks with this cat! Great response! Now I feel better about our future.

 

And your response is what? Spend more time faking calls and working your side hustle?

 

Typical!! Lots of dull tools in the box here at BMS.

 

link? I don’t see this information anywhere. Was the patient on a different drug prior?

 

Common knowledge now.

 

False lies, Ocrevus does not have the PML cases you tout. Get the facts correct, Zep is not going to be the leader we’ve been led to believe

 

Ocrevus hasn’t had PML cases? Please do your homework. You’re supposed to be a salesperson and knowledgeable of the category you are selling in. What the heck have you been doing since last March besides Netflix and posting on this site? Have some professional pride and know what you are talking about before opening your mouth.

https://www.medscape.com/viewarticle/929728

 

So for a drug that’s been on the market for 5 years, has reported in total 8 cases (most with patients receiving prior therapy, you’re going to say it is widespread? Have some professional pride yourself and understand the difference between a few and a lot. Clinicians know the difference and have read the data.

 

Tenth case (since launch in March 2017...4 years ago) reported in March.
No other therapy prior to Ocrevus for this new case.

 

No case of PML listed in FAERS

 

10 confirmed cases on ocrevus. 9/10 are considered carry over from gilenya and tysabri. The 10th case which was fatal the patient had only been treated with ocrevus for 2 years. The issue is after 2 years PMl developed which could signal a concern.